February 19, 2018Neurology
According to an article published in Neurology (7 February 2018), research into curious bright spots in the eyes on stroke patients' brain images could one day alter the way these individuals are assessed and treated. A team of scientists at the NIH found that a chemical routinely given to stroke patients undergoing brain scans can leak into their eyes, highlighting those areas and potentially providing insight into their strokes. The eyes glowed brightly on those images due to gadolinium, a harmless, transparent chemical often given to patients during magnetic resonance imaging (MRI) scans to highlight abnormalities in the brain. In healthy individuals, gadolinium remains in the blood stream and is filtered out by the kidneys. However, when someone has experienced damage to the blood-brain barrier, which controls whether substances in the blood can enter the brain, gadolinium leaks into the brain, creating bright spots that mark the location of brain damage.
Previous research had shown that certain eye diseases could cause a similar disruption to the blood-ocular barrier, which does for the eye what the blood-brain barrier does for the brain. The authors discovered that a stroke can also compromise the blood-ocular barrier and that the gadolinium that leaked into a patient's eyes could provide information about his or her stroke.
The authors performed MRI scans on 167 stroke patients upon admission to the hospital without administering gadolinium and compared them to scans taken using gadolinium two hours and 24 hours later. Because gadolinium is transparent, it did not affect patients' vision and could only be detected with MRI scans. Roughly three-quarters of the patients experienced gadolinium leakage into their eyes on one of the scans, with 66% showing it on the two-hour scan and 75% on the 24-hour scan. The phenomenon was present in both untreated patients and patients who received a treatment, called tPA, to dissolve the blood clot responsible for their strokes. Gadolinium was typically present in the front part of the eye, called the aqueous chamber, after two hours, and in a region towards the back, called the vitreous chamber, after 24 hours. Patients showing gadolinium in the vitreous chamber at the later timepoint tended to be of older age, have a history of hypertension, and have more bright spots on their brain scans, called white matter hyperintensities, that are associated with brain aging and decreased cognitive function.
In a minority of patients, the two-hour scan showed gadolinium in both eye chambers. The strokes in those patients tended to affect a larger portion of the brain and cause even more damage to the blood-brain barrier than the strokes of patients with a slower pattern of gadolinium leakage or no leakage at all. The findings raise the possibility that, in the future, clinicians could administer a substance to patients that would collect in the eye just like gadolinium and quickly yield important information about their strokes without the need for an MRI.
According to the authors, it is much easier for us to look inside somebody's eye than to look into somebody's brain, so if the eye truly is a window to the brain, we can use one to learn about the other. Despite the relationship between gadolinium leakage and stroke severity, the phenomenon was not found to be related to the level of disability the patients developed following their strokes. It also remains unclear whether gadolinium can enter the eye in healthy people.